Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05883761
Other study ID # EG0259
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 7, 2021
Est. completion date September 30, 2023

Study information

Verified date May 2023
Source Elizabeth Glaser Pediatric AIDS Foundation
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to assess the birth outcomes of HIV-positive women delivering in hospitals in Eswatini who are receiving dolutegravir (DTG) or other anti-retroviral (ARV) drug regimens. The main question the study aims to answer is, what is the proportion of neural tube defects among live and stillborn infants delivered by: - HIV-positive women on DTG at conception - HIV-negative women - HIV-positive women on non-DTG ARV at conception Participants will be interviewed for information on HIV testing and antiretroviral therapy history, other medical history of selected conditions (e.g., diabetes, malaria, TB) and potential birth defect exposures. Photographs will be taken of the infants. Data on mothers' pregnancy history, birth outcomes, and HIV and ARV information (as applicable) will be collected from patient records.


Description:

This is an observational study conducted at five high volume hospitals in Eswatini, in which birth defect and other data will be collected at the time of delivery (or hospital admission for miscarriages and medical abortions) for all women. The overall aim of this study is to evaluate the birth outcomes of HIV-positive women who are receiving DTG or other ARV drug regimens. The primary research objectives are to: 1) determine the proportion of neural tube defects among live and stillborn infants delivered by HIV-positive women on DTG at conception; 2) determine the proportion of neural tube defects among live and stillborn infants delivered by HIV-negative women; and 3) determine the proportion of neural tube defects among live and stillborn infants delivered by HIV-positive women on non-DTG ART at conception. Secondary objectives are to determine overall general prevalence of major external birth defects and other pregnancy outcomes and any associations with other factors (e.g., maternal age, gravida). Data on mothers' pregnancy history, birth outcomes, and HIV and ARV information (as applicable) are collected from patient charts, registers, reporting forms and databases for all women. Women of live or stillborn infants with birth defects are consented for interviews capturing detailed history and exposure data and photographs of newborns' birth defects. Data collection will be for approximately 24 months. Blinded interview data and photographs are reviewed by a medical geneticist for confirmatory defect diagnosis. We will describe rates and 95% confidence intervals (CI) for birth defects among infants by maternal HIV and ART status.


Recruitment information / eligibility

Status Completed
Enrollment 50075
Est. completion date September 30, 2023
Est. primary completion date September 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group N/A and older
Eligibility Surveillance component includes all deliveries/admissions as defined in study population description. For a subset of the population recruited for additional data collection: Inclusion Criteria: - women whose live or stillborn infant has birth defect as identified by a midwife or other clinician at the study hospital - willing to provide informed consent Exclusion Criteria: - unable to provide informed consent

Study Design


Locations

Country Name City State
Swaziland Good Shepherd Hospital Lubombo
Swaziland Mankayane Government Hospital Manzini
Swaziland Raleigh Fitkin Memorial Hospital Manzini
Swaziland Mbabane Government Hospital Mbabane
Swaziland Hlathikhulu Hospital Shiselweni

Sponsors (3)

Lead Sponsor Collaborator
Elizabeth Glaser Pediatric AIDS Foundation George Washington University, Ministry of Health Eswatini

Country where clinical trial is conducted

Swaziland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of neural tube defects (NTDs) among live and stillborn infants delivered by HIV-positive women on DTG at conception. Number of live and stillborn infants with NTDs divided by the total number of live and stillborn infants of HIV-positive women on DTG at conception 24 months
Primary Proportion of neural tube defects (NTDs) among live and stillborn infants delivered by HIV-negative women Number of live and stillborn infants with NTDs divided by the total number of live and stillborn infants of HIV-negative women 24 months
Primary Proportion of neural tube defects (NTDs) among live and stillborn infants delivered by HIV-positive women on non-DTG ARV at conception Number of live and stillborn infants with NTDs divided by the total number of live and stillborn infants of HIV-positive women on non-DTG ARV at conception 24 months
Secondary Prevalence of major external birth defects among all live and stillborn infants regardless of maternal HIV or ART status. Number of live and stillborn infants with major external birth defects divided by the total number of live and stillborn infants among all women regardless of HIV or ART status 24 months
Secondary Proportion of other pregnancy outcomes Number of live and stillborn infants with low birthweight and pre-term delivery divided by the total number of live infants among women (overall and by HIV/ART status); number of stillborn infants among all pregnancies, including miscarriages 24 months
See also
  Status Clinical Trial Phase
Completed NCT00766571 - Clinical and Genetic Studies of VACTERL Association
Recruiting NCT05394363 - Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents
Not yet recruiting NCT05393167 - Congenital Anomalies in Infants of Diabetic Mother
Not yet recruiting NCT05547308 - Evaluation of 3D Printed Myoelectric Prosthetic Devices in Children With Upper Congenital Limb Deficiency N/A
Recruiting NCT05151042 - Digital Occlusal Wafer Versus Waferless Distal Segment Repositioning for BSSO in Skeletal Mandibular Deformities N/A
Recruiting NCT05738954 - Pattern Recognition and Anomaly Detection in Fetal Morphology Using Deep Learning and Statistical Learning
Recruiting NCT02505464 - Pregnancies Complicated by Fetal Anomalies
Recruiting NCT02595307 - Improving Informed Consent for Cleft Palate Repair N/A
Completed NCT00477594 - Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia Phase 2
Completed NCT00062452 - Esophageal Motility and Airway Defenses Among Infants N/A
Recruiting NCT05763615 - 3D Modeling of the Cervico-facial Region and Cranial Nerve Tractography: IMAG 2 ORL Project N/A
Terminated NCT02351726 - Mitroflow DL Post Approval Study- North America N/A
Recruiting NCT04591392 - Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD N/A
Not yet recruiting NCT05231447 - Birth Defect Registry in South West Region of France
Completed NCT02429947 - An Analysis of the Symptomatic Domains Most Relevant to Charcot Marie Tooth Neuropathy (CMT) Patients N/A
Completed NCT01653392 - BioThrax® (Anthrax) Vaccine in Pregnancy Registry
Completed NCT00607373 - Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia Phase 3
Completed NCT00362180 - Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration Phase 2
Active, not recruiting NCT02987387 - COMPASSION XT PAS - Post-approval Study of the SAPIEN XT THV in Patients With Pulmonary Valve Dysfunction
Completed NCT02875860 - 'TOTAL' (Tracheal Occlusion To Accelerate Lung Growth) Trial Phase 2